BioNTech SE Reports Promising Phase‑2 Results for Trastuzumab Pamirtecan (BNT323)
BioNTech SE (Xetra: BNT) announced Phase‑2 data for its antibody‑drug conjugate (ADC) Trastuzumab Pamirtecan (BNT323) during the Society of Gynecologic Oncology (SGO) annual meeting. The study involved patients with advanced endometrial carcinoma that expresses the HER2 receptor and who had relapsed after first‑line chemotherapy.
Efficacy
| HER2 Expression | Objective Response Rate (ORR) | Median Progression‑Free Survival (PFS) |
|---|---|---|
| All tested patients | 47.9 % | 8.1 months |
| IHC 3+ (high expression) | > 70 % | — |
| IHC 2+ | 40.4 % | — |
| IHC 1+ | 33.9 % | — |
The data demonstrate that BNT323 achieves an ORR far exceeding the typical ~15 % seen with chemotherapy in this indication. For patients with high HER2 expression, the response rate exceeds 70 %, suggesting a meaningful therapeutic niche that extends beyond the FDA‑approved indication for the competitor Enhertu (which is limited to IHC 3+ patients).
Safety
Treatment‑related Grade ≥ 3 adverse events occurred in 46.9 % of patients. Serious interstitial lung disease was reported in 4.8 %. The safety profile was considered manageable across all HER2 expression levels.
Regulatory Context
- BNT323 carries FDA Fast Track and Breakthrough Therapy designations.
- A Biologics License Application is scheduled for 2026, with a confirmatory Phase‑3 study (Fern‑EC‑01) ongoing.
- The data may support a broader approval covering low‑ to high‑HER2‑expressing patients, potentially opening a new patient segment that has limited treatment options.
Market Reaction
Following the release of the data:
- BofA Securities raised its price target for BioNTech.
- The shares have risen approximately 10 % over the preceding seven trading days, trading near €85.20, just above the 50‑day moving average.
- Analyst commentary emphasizes that while the indication is modest in scope, the ADC’s performance positions BioNTech for a strategic bridge into larger oncology markets.
Corporate Developments
- The company will hold a virtual general‑meeting on 15 May.
- The agenda includes a substantive capital‑raising measure, details of which have not yet been disclosed.
Summary
BioNTech SE’s Phase‑2 results for Trastuzumab Pamirtecan demonstrate robust activity across HER2 expression levels in advanced endometrial carcinoma, with a manageable safety profile. The findings support the company’s ongoing regulatory strategy and are expected to influence the share price positively.
